{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T04:54:38Z","timestamp":1795236878547,"version":"4.10.3"},"reference-count":18,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2024,2,11]],"date-time":"2024-02-11T00:00:00Z","timestamp":1707609600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019211","name":"AbbVie Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019211","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001127","name":"Genentech Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001127","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Venetoclax\u2010azacitidine is approved for treatment of patients with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive chemotherapy based on the interim overall survival (OS) analysis of the VIALE\u2010A study (NCT02993523). Here, long\u2010term follow\u2010up is presented to address survival benefit and long\u2010term outcomes with venetoclax\u2010azacitidine. Patients with newly diagnosed AML who were ineligible for intensive chemotherapy were randomized 2:1 to receive venetoclax\u2010azacitidine or placebo\u2010azacitidine. OS was the primary endpoint; complete remission with\/without blood count recovery (CR\/CRi) was a key secondary endpoint. This final analysis was conducted when 100% of the predefined 360 OS events occurred. In VIALE\u2010A, 431 patients were enrolled to venetoclax\u2010azacitidine (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009286) or placebo\u2010azacitidine (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009145). At 43.2\u2009months median follow\u2010up, median OS was 14.7\u2009months (95% confidence interval [CI], 12.1\u201318.7) with venetoclax\u2010azacitidine, and 9.6\u2009months (95% CI, 7.4\u201312.7) with placebo\u2010azacitidine (hazard ratio, 0.58 [95% CI, 0.47\u20130.72],\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u2009.001); the estimated 24\u2010month OS rate was 37.5% and 16.9%, respectively. Median OS for patients with\n                    <jats:italic>IDH1\/2<\/jats:italic>\n                    mutations and those with measurable residual disease responses was reached in this final analysis. CR\/CRi rate was similar to interim analysis. Any\u2010grade hematologic and gastrointestinal adverse events were most common in venetoclax\u2010azacitidine and placebo\u2010azacitidine arms, including thrombocytopenia (47% and 42%) and neutropenia (43% and 29%). No new safety signals were identified. Long\u2010term efficacy and safety confirm venetoclax\u2010azacitidine is an improvement in standard\u2010of\u2010care for patients with AML who are not eligible for intensive chemotherapy because of advanced age or comorbidities.\n                  <\/jats:p>","DOI":"10.1002\/ajh.27246","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T01:29:50Z","timestamp":1707701390000},"page":"615-624","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":265,"title":["Long\u2010term follow\u2010up of\n                    <scp>VIALE\u2010A<\/scp>\n                    : Venetoclax and azacitidine in chemotherapy\u2010ineligible untreated acute myeloid leukemia"],"prefix":"10.1002","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1284-8266","authenticated-orcid":false,"given":"Keith W.","family":"Pratz","sequence":"first","affiliation":[{"name":"Abramson Cancer Center University of Pennsylvania  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4921-5809","authenticated-orcid":false,"given":"Brian A.","family":"Jonas","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Malignant Hematology\/Cellular Therapy and Transplantation University of California Davis School of Medicine  Sacramento California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9129-3424","authenticated-orcid":false,"given":"Vinod","family":"Pullarkat","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell transplantation and Gehr Family Center for Leukemia Research City of Hope Comprehensive Cancer Center  Duarte California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Thirman","sequence":"additional","affiliation":[{"name":"Section of Hematology and Oncology, Department of Medicine University of Chicago Medicine  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2118-6302","authenticated-orcid":false,"given":"Jacqueline S.","family":"Garcia","sequence":"additional","affiliation":[{"name":"Dana\u2010Farber Cancer Institute, Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"D\u00f6hner","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III Ulm University Hospital  Ulm Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3332-4525","authenticated-orcid":false,"given":"Christian","family":"R\u00e9cher","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Toulouse III Paul Sabatier  Toulouse France"},{"name":"Cancer Research Center of Toulouse  Toulouse France"},{"name":"Centre Hospitalier Universitaire de Toulouse Institut Universitaire du Cancer de Toulouse Oncopole  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Fiedler","sequence":"additional","affiliation":[{"name":"University Medical Center Hamburg\u2010Eppendorf  Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhito","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Aichi Cancer Center  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9437-9151","authenticated-orcid":false,"given":"Jianxiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Institute of Hematology and Hospital of Blood Disease Chinese Academy of Medical Sciences, Peking Union Medical College  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung\u2010Soo","family":"Yoon","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Seoul National University College of Medicine  Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofir","family":"Wolach","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center Petah Tikva and Tel\u2010Aviv University  Tel\u2010Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su\u2010Peng","family":"Yeh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine China Medical University Hospital  Taichung Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Leber","sequence":"additional","affiliation":[{"name":"Department of Medicine McMaster University  Hamilton Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Esteve","sequence":"additional","affiliation":[{"name":"Department of Hematology Hospital Clinic, August Pi i Sunyer Biomedical Research Institute  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Mayer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine University Hospital Brno and Masaryk University  Brno Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimmo","family":"Porkka","sequence":"additional","affiliation":[{"name":"Department of Hematology Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki  Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1rp\u00e1d","family":"Ill\u00e9s","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Hematology University of Debrecen  Debrecen Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto M.","family":"Lemoli","sequence":"additional","affiliation":[{"name":"Clinic of Hematology, Department of Internal Medicine University of Genoa  Genoa Italy"},{"name":"IRCCS San Martino Hospital Genoa  Genoa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Turgut","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Internal Medicine, Division of Hematology Ondokuz Mayis University  Samsun Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Ku","sequence":"additional","affiliation":[{"name":"Genentech Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Miller","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Zhang","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2594-9696","authenticated-orcid":false,"given":"Brenda","family":"Chyla","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalaja","family":"Potluri","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney D.","family":"DiNardo","sequence":"additional","affiliation":[{"name":"Department of Leukemia, Division of Cancer Medicine University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,2,11]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1406184"},{"key":"e_1_2_11_3_1","unstructured":"SEER data base: cancer stat facts: leukemia \u2013 acute myeloid leukemia (AML). Accessed January 25 2023.https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33458"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.036"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196"},{"key":"e_1_2_11_9_1","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE)","year":"2010"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01546"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4600"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507471"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0257-z"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1183"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3405"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3467"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-375758"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000844928.23775.aa"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26692"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.27246","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T07:16:03Z","timestamp":1714029363000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.27246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,11]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1002\/ajh.27246"],"URL":"https:\/\/doi.org\/10.1002\/ajh.27246","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,11]]},"assertion":[{"value":"2024-01-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}